Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic, serologic or clinical evidence of germ cell tumor.~* Patients scheduled to receive a 5 day fractionated cisplatin-based combination chemotherapy on permitted regimens~* Prior chemotherapy is allowed. Patients will be stratified based on previous treatment.~* Male patients 15 years of age or older at time of registration.~* Patient will provide written informed consent and authorization to release personal health information.~Exclusion Criteria:~* No known history of anticipatory nausea or vomiting.~* No use of another antiemetic agent within 72 hours prior to beginning chemotherapy.~* No known central nervous system (CNS) metastasis.~* No known hypersensitivity to any component of study regimen.~* No concurrent participation in a clinical trial which involves another investigational agent.~* No use of warfarin while on study.~* No use of agents expected to induce the metabolism of aprepitant which include: Rifampin, Rifabutin, Phenytoin, Carbamazepine, and barbiturates.~* No use of agents which may impair metabolism of aprepitant which include: Cisapride, macrolide antibiotics (Erythromycin, Clarithromycin, Azithromycin), azole antifungal agents (Ketoconazole, Itraconazole, Voriconazole, Fluconazole), Amifostine, Nelfinavir and Ritonavir.

- Gender: MALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Aprepitant, Then Placebo (Type: EXPERIMENTAL): Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
- Arm B: Placebo, Then Aprepitant (Type: EXPERIMENTAL): Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2

Based on this trial design, predict the completion outcome and termination type (if applicable).